Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: Results from an international trial of 9461 patients

Circulation

Volumn 101, Issue 22, 2000, Pages 2557-2567

  Boersma, Eric ^a   Pieper, Karen S ^b   Steyerberg, Ewout W ^a   Wilcox, Robert G ^c   Chang, Wei Ching ^d   Lee, Kerry L ^b   Akkerhuis, K Martijn ^a   Harrington, Robert A ^b   Deckers, Jaap W ^a   Armstrong, Paul W ^d   Lincoff, A Michael ^e   Califf, Robert M ^b   Topol, Eric J ^e   Simoons, Maarten L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angina; Coronary disease; Myocardial infarction; Prognosis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; NITRATE; PLACEBO;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; ST SEGMENT;

EID: 0034612223     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.22.2557     Document Type: Article

References (23)

1. The Reperfusion Therapy Consensus Group. Selection of reperfusion therapy for individual patients with evolving myocardial infarction. Eur Heart J. 1997;18:1371-1381.
2. Boersma E, Steyerberg EW, Van der Vlugt MJ, et al. Reperfusion therapy for acute myocardial infarction: which strategy for which patient? Drugs. 1998;56:31-48.
3. Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation. 1995;91:1659-1668.
4. Simoons ML, Arnold AER. Tailored thrombolytic therapy: a perspective. Circulation. 1993;88:2556-2564.
5. Boersma E, Vlugt van der M, Arnold AER, et al. Estimated gain in life expectancy: a simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. Eur Heart J. 1996;17:64-75.
6. Maseri A, Rebuzzi AG, Cianflone D. Need for a composite risk stratification of patients with unstable coronary syndromes tailored to clinical practice. Circulation. 1997;96:4141-4142.
7. Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation. 1998;98:1860-1868.
8. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
9. Harrington RA. Clinical trials in acute coronary syndromes: lessons from PURSUIT. Eur Heart J. 1999;1(suppl R):R28-R34.
10. Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, eds. Second International Symposium on Information Theory. Budapest, Hungary: Akademia Kiado; 1973: 267-281.
11. Smith PL. Splines as a useful and convenient statistical tool. Am Statistician. 1979;33:57-62.
12. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
13. Little RJ. Regression with missing X's: a review. J Am Stat Assoc. 1992;87:1227-1237.
14. S-Plus Guide to Statistical and Mathematical Analysis, Version 3.3. Seattle, Wash: Statistical Sciences; 1996.
15. Kendal DG. Rank Correlation Methods. 3rd ed. London, UK: Charles Griffin; 1962.
16. Gong G. Cross-validation, the jackknife, and the bootstrap: excess error estimation in forward logistic regression. J Am Stat Assoc. 1986;81: 108-113.
17. Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation. 2000;101:751-757.
18. Lindahl B, Venge P, Wallentin L, for the FRISC Study Group. Relation between troponin-T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation. 1996;93:1651-1657.
19. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
20. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
21. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340:1623-1629.
22. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI): DANish trial in Acute Myocardial Infarction. Circulation. 1997;96:748-755.
23. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999; 100:2045-2048.